{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:10:47Z","timestamp":1769829047246,"version":"3.49.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for decades as a treatment for disseminated abdominal malignancies, including pseudomyxoma peritonei and peritoneal mesothelioma. HIPEC had been used to treat recurrent ovarian cancer only when curative options were lacking, but new data indicate that it may be suitable as a primary treatment for patients with late-stage epithelial ovarian cancer, increasing the recurrence-free time interval and improving quality of life. However, treatment can be challenging because of patient trauma from surgery, combined with the toxicity and high temperature of the chemotherapeutic agents. This article reviews HIPEC and its targeted intraoperative and postoperative management.<\/jats:p>","DOI":"10.1097\/01.jaa.0000735800.98948.bb","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T22:11:09Z","timestamp":1627510269000},"page":"50-53","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer"],"prefix":"10.1097","volume":"34","author":[{"given":"Shilpa","family":"Gajarawala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Pelkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Dorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tri","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2","key":"R1-20250607","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonzalez-Moreno","year":"2010","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"R2-20250607","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"R3-20250607","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","article-title":"Optimizing treatment in recurrent epithelial ovarian cancer","volume":"17","author":"Corrado","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"R4-20250607","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1586\/14737140.1.1.142","article-title":"Intraperitoneal chemotherapy in the management of malignant disease","volume":"1","author":"Markman","year":"2001","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"R5-20250607","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Womens Health"},{"issue":"10177","key":"R7-20250607","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"7","key":"R9-20250607","first-page":"19","article-title":"Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal","volume":"23","author":"Samartzis","year":"2018","journal-title":"J BUON"},{"issue":"suppl 8","key":"R10-20250607","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"R11-20250607","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"6","key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d'investigateurs nationaux pour les etudes des cancers de l'ovaire (GINECO)","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"R13-20250607","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jso.24666","article-title":"Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer","volume":"116","author":"Magge","year":"2017","journal-title":"J Surg Oncol"},{"issue":"28","key":"R14-20250607","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"R15-20250607","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ygyno.2019.01.025","article-title":"Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy","volume":"153","author":"Lim","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"3","key":"R16-20250607","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2018.09.007","article-title":"It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer","volume":"151","author":"Zivanovic","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"R17-20250607","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"R18-20250607","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.esxm.2017.07.001","article-title":"Anatomic sites and associated clinical factors for deep dyspareunia","volume":"5","author":"Yong","year":"2017","journal-title":"Sex Med"},{"issue":"6","key":"R19-20250607","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ejso.2016.09.008","article-title":"Best practice for perioperative management of patients with cytoreductive surgery and HIPEC","volume":"43","author":"Raspe","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"R20-20250607","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.soc.2012.07.001","article-title":"Hyperthermic intraperitoneal chemotherapy: methodology and safety considerations","volume":"21","author":"Gonzalez-Moreno","year":"2012","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"R21-20250607","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","article-title":"Heated IntraPEritoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review","volume":"26","author":"Hotouras","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"R22-20250607","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2044.2007.05380.x","article-title":"Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"63","author":"Schmidt","year":"2008","journal-title":"Anaesthesia"},{"issue":"3","key":"R23-20250607","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ACO.0b013e32835347b2","article-title":"Anesthetic management in patients undergoing hyperthermic chemotherapy","volume":"25","author":"Raspe","year":"2012","journal-title":"Curr Opin Anaesthesiol"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1477-7819-9-169","article-title":"Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC)","volume":"9","author":"Cooksley","year":"2011","journal-title":"World J Surg Oncol"},{"issue":"2","key":"R25-20250607","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/sja.SJA_545_18","article-title":"Cytoreductive onco-surgery with combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy: perioperative challenges","volume":"13","author":"Dattatri","year":"2019","journal-title":"Saudi J Anaesth"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000735800.98948.bb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:02:04Z","timestamp":1749322924000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000735800.98948.bb"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000735800.98948.bb","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}